Since August 1, 2023, the renowned Metavectum GmbH is now called iQMedix GmbH. It is a new beginning in a new environment. Metavectum, a leading gene laboratory, is known for its pioneering developments in the field of gene expression of circulating tumor cells. Metavectum's proven techniques and products will be retained, and with new investments and a strengthened team of highly qualified experts, the company will work intensively to further advance personalized cancer therapy and pave innovative paths for the future of individualized, causal medicine.
Thank you for your trust. We look forward to moving forward with you into a promising future.
With best regards, yours
Dr. Bert Steffan, Dr. Bernd Becker, Dr. Reinhard Becker
Managing Director iQMedix GmbH
